Instruction for use: Falimint

Active substance Acetylaminonitropropoxybenzene

ATX code R02AA20 Other drugs

Pharmacological group

Antitussives

Antiseptics and disinfectants

Other non-narcotic analgesics, including non-steroidal and other anti-inflammatory drugs

Nosological classification (ICD-10)

J02.9 Acute pharyngitis, unspecified

purulent pharyngitis, Acute nasopharyngitis,Limfonodulyarny pharyngitis

J03.9 Acute tonsillitis, unspecified (angina agranulocytic)

Sore throat infections, Acute tonsillitis, Angina, Follicular tonsillitis, Angina alimentary-hemorrhagic, Secondary sore throat, Sore throat primary, Angina follicular, Angina, Inflammatory diseases of the tonsils, Catarrhal angina, Lacunar angina, Acute Sore Throat, Tonsillitis, Tonsillitis acute, Tonsillar angina, Follicular sore throat, Bacterial tonsillitis

J04 Acute laryngitis and tracheitis

Cough in diseases of the upper respiratory tract, Laryngitis, acute Laryngitis, tracheitis sharp, pharyngolaryngitis, Infectious-inflammatory diseases of ENT organs

K05 Gingivitis and periodontal disease

Gingivitis, Inflammatory Gum Disease, Inflammatory diseases of the oral cavity, Hyperplastic gingivitis, Diseases of the mouth, Catarrhal gingivitis, Erythematous gingivitis, Ulcerative gingivitis, Exacerbation of inflammatory diseases of the pharynx and oral cavity, Bleeding from the gums, Epstein cysts

K12 Stomatitis and Related Lesions

Bacterial stomatitis, Inflammatory diseases of the oral cavity, Inflammatory diseases of tissues of the oral cavity, Inflammatory processes in the oral cavity, Fungal diseases of the mouth, Fungal infections of the oral cavity, Fungal infections and inflammatory diseases of the mouth, Diseases of the mouth, Infectious-inflammatory disease of the oral cavity, Exacerbation of inflammatory diseases of the pharynx and oral cavity, Stomatitis, Angular stomatitis, Chronic recurrent stomatitis, Ulcerative necrotic diseases of the oral mucosa, Ulcerative necrotic gingivostomatitis, Ulcerative stomatitis, Erosive-ulcerative lesion of the oral mucosa, Erosive-ulcerative lesions of the mucous membrane of the oral cavity, Erotic mucous membrane of the oral cavity, Recurrent ulcerative stomatitis

R05 Cough

Cough, Cough in the preoperative period, Cough with allergic conditions, Cough with bronchitis, Cough in inflammatory diseases of the lung and bronchus, Cough in diseases of the upper respiratory tract, Coughing with a cold, Cough with difficult expectoration of viscous, Cough with difficult expectoration, dry Cough, nonproductive cough, paroxysmal cough, Paroxysmal non-productive cough, productive cough, Reflex cough, Coughing, spasmodic cough, Dry painful cough, The dry non-productive cough, Dry irritating cough, Cough with bronchial asthma, Cough in tuberculosis

Z01.2 Dental examination

tooth Extirpation, Anesthesia of mucous membranes, Dental intervention

Z46.3 Fitting and fitting the denture

Composition and form of release

Dragee 1 dragee

acetylaminonitropropoxybenzene 25 mg

auxiliary substances: sucrose; gelatin; fat solid; talc; copovidone; silicon dioxide colloidal; magnesium stearate

shell: sucrose; talc; glucose syrup; simethicone emulsion 30%; liquid paraffin; paraffin wax

in a blistere of 20 pcs .; in a pack of cardboard 1 blister.

Description of dosage form

Round, biconvex dragees, almost white, with a smooth surface, uniform in appearance.

pharmachologic effect

Pharmacological action - local anesthetic, antiseptic.

Eliminates unproductive irritating cough, with resorption creates a feeling of coolness in the mouth and throat. Has analgesic, refreshing, cooling effect. Does not exert a drying effect on mucous membranes, does not cause a feeling of numbness in the mouth.

Indications

Inflammatory diseases of the respiratory tract (tonsillitis, pharyngitis, laryngitis).

Inflammatory diseases of the oral cavity (gingivitis, stomatitis).

Reflex cough (unproductive, irritating).

Preparation for instrumental studies of the oral cavity and throat, with the removal of casts and fitting of dentures.

Contraindications

Hypersensitivity to the components of the drug.

pregnancy and lactation

It is not recommended (due to the lack of sufficient experience of using Falimint during pregnancy and during breastfeeding).

Side effects

Individual intolerance is possible.

Dosing and Administration

Inside, keep in the mouth until complete resorption, without chewing, 25-50 mg 3-5 times a day (no more than 10 times).

Precautionary measures

Do not use for a long time. Immediately after use, refrain from eating food and liquids.

storage Conditions

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after the expiry date printed on the package.